ETF Runner: ProShares UltraPro Nasdaq Biotechnology (UBIO) Rises 0.72% for Nov 29

November 29, 2016 - By Darrin Black   ·   0 Comments

Nov 29 is a positive day so far for ProShares UltraPro Nasdaq Biotechnology (NASDAQ:UBIO) as the ETF is active during the day after gaining 0.72% to hit $25.22 per share. The exchange traded fund has 41.31 million net assets and 6.63% volatility this month.

Over the course of the day 23,653 shares traded hands, as compared to an average volume of 165,520 over the last 30 days for ProShares UltraPro Nasdaq Biotechnology (NASDAQ:UBIO).

The ETF is -55.22% of its 52-Week High and 57.40% of its low, and is currently having ATR of 1.97. This year’s performance is -52.74% while this quarter’s performance is -13.29%.

The ETF’s YTD performance is -65.53%, the 1 year is -62.66% and the 3 year is NaN%.

The ETF’s average P/E ratio is 18.14, the price to book is 3.25, the price to sales is 4.64 and the price to cashflow is 9.14. It was started on 6/23/2015. The fund’s top holdings are: Nasdaq Biotechnology Index Swap Societe Generale for 166.38% of assets, Nasdaq Biotechnology Index Swap Bank Of America Na for 52.79%, Celgene Corporation for 6.85%, Gilead Sciences Inc. for 6.72%, Biogen Inc. for 6.56%, Amgen Inc. for 5.94%, Regeneron Pharmaceuticals Inc. for 5.50%, Alexion Pharmaceuticals Inc. for 3.71%, Mylan N.V. for 3.08%, Illumina Inc. for 2.89%. The ETF sector weights are: Healthcare 100.00%. The ETF currently as yield.

More notable recent Proshares UltraPro Nasdaq Biotechnology (NASDAQ:UBIO) news were published by: which released: “Proshares UltraPro NASDAQ Biotechnology” on March 08, 2014, also with their article: “ProShares Releases 2 New Leveraged Biotech ETFs” published on June 23, 2015, published: “Biotech ETFs Unwind Political Risk After Trump Victory” on November 11, 2016. More interesting news about Proshares UltraPro Nasdaq Biotechnology (NASDAQ:UBIO) were released by: and their article: “Biotech ETFs Still in Fragile Spots” published on November 25, 2016 as well as‘s news article titled: “CAR T-Cell Stocks a Better Way to Leverage Biotech Than New 3x ETFs” with publication date: June 25, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Darrin Black

Readers Comments (0)

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News